Target identification
BostonGene leverages proprietary genomic and transcriptomic databases to pinpoint the most promising cancer types for drug candidates. By analyzing drug targets across tumor and normal cells, BostonGene identifies patients most likely to benefit from treatment.
Drug target transcriptomics
BostonGene mines a proprietary pan-cancer database of over 100,000 transcriptomic profiles for drug target expression data to optimize drug development strategies.
Cancer type selection
Identify the most promising indications by analyzing target expression across cancer types.
Adverse event assessment
Predict on-target, off-tumor effects by evaluating target expression levels in normal tissues.
TME reconstruction
Capture immune modulation by assessing target expression in immune cell populations.
Tumor vs TME expression
Ensure target specificity by identifying if target is located primarily on tumor or TME cells.
Drug target genomics
BostonGene interrogates a proprietary whole exome and whole transcriptome sequencing database for comprehensive genomic profiling of single nucleotide variants, copy number alterations, insertions/deletions and fusions.
Alteration prevalence
Align target-associated genomic alterations with specific cancer types for precise indication matching.
Alteration co-occurrence
Analyze concurrent genomic alterations across cancer types to identify therapeutic combinations or synthetic lethality strategies.
Drug mechanism of action analysis
BostonGene performs mechanism of action confirmation and validation from preclinical models by evaluating the downstream effects of target inhibition. BostonGene delivers actionable insights with unmatched precision utilizing advanced technologies:
- Next-generation sequencing,
- Flow cytometry,
- Tissue imaging.
Case example: Target population discovery
Pharma challenge
Identify patients who respond to a novel ADC targeting gene X.
BostonGene approach
Conducted a retrospective analysis of BostonGene's extensive database to identify patients with high expression of gene X.
Result
Developed a targeted strategy to focus on patients with the highest gene X expression, maximizing the likelihood of identifying potential therapy responders.
Identify patients who respond to a novel ADC targeting gene X.
BostonGene approach
Conducted a retrospective analysis of BostonGene's extensive database to identify patients with high expression of gene X.
Result
Developed a targeted strategy to focus on patients with the highest gene X expression, maximizing the likelihood of identifying potential therapy responders.
